基于弥散加权MRI与肿瘤控制概率的胶质母细胞瘤等毒剂量递增放疗的计算机模拟研究
结果表明基于DW-MRI的体素级个体化剂量递增可提高肿瘤控制概率。
要点
- DW-MRI的ADC图可估算GTV内细胞密度并生成TCP图,识别低TCP区域作为BTV。
- 对BTV行等毒SIB 3.60–16.80 Gy可使队列TCP平均提高8.44%。
- 该方法为胶质母细胞瘤个体化体素级放疗提供思路,但尚属计算机模拟。
核心结论
- 基于DW-MRI细胞密度指导的BTV等毒SIB可提高胶质母细胞瘤的肿瘤控制概率,并提供个体化放疗可能。
研究设计与样本
- 利用治疗前DW-MRI衍生的ADC图,基于已发表数据计算局部细胞密度。
- 采用TCP模型从细胞密度值计算TCP图,并以同步整合推量(SIB)对BTV进行剂量递增。
关键影像表现/征象
- 原文未报告具体影像征象,仅利用ADC图估算细胞密度并生成TCP图。
诊断标准与关键数值
- BTV定义为推量前预期TCP处于该患者TCP范围最低四分位的体素。
- SIB剂量选择为使BTV内TCP升高至与全肿瘤平均TCP相匹配。
- SIB剂量范围为3.60 Gy至16.80 Gy,等毒实施后队列TCP平均提高8.44%(范围7.19–16.84%)。
- 危及器官剂量仍低于其耐受剂量。
临床应用与阅片要点
- 阅片时可关注ADC图提示的细胞密度异质性,辅助识别潜在低TCP区域。
- 目前仅为计算机模拟结果,尚不能直接用于临床报告或剂量处方。
局限性
- 细胞密度计算基于已发表数据,TCP模型假设可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Glioblastoma (GBM) is the most common malignant primary brain tumor with local recurrence after radiotherapy (RT), the most common mode of failure. Standard RT practice applies the prescription dose uniformly across tumor volume disregarding radiological tumor heterogeneity. We present a novel strategy using diffusion-weighted (DW-) MRI to calculate the cellular density within the gross tumor volume (GTV) in order to facilitate dose escalation to a biological target volume (BTV) to improve tumor control probability (TCP).
METHODS: The pre-treatment apparent diffusion coefficient (ADC) maps derived from DW-MRI of ten GBM patients treated with radical chemoradiotherapy were used to calculate the local cellular density based on published data. Then, a TCP model was used to calculate TCP maps from the derived cell density values. The dose was escalated using a simultaneous integrated boost (SIB) to the BTV, defined as the voxels for which the expected pre-boost TCP was in the lowest quartile of the TCP range for each patient. The SIB dose was chosen so that the TCP in the BTV increased to match the average TCP of the whole tumor.
RESULTS: By applying a SIB of between 3.60 Gy and 16.80 Gy isotoxically to the BTV, the cohort's calculated TCP increased by a mean of 8.44% (ranging from 7.19 to 16.84%). The radiation dose to organ at risk is still under their tolerance.
CONCLUSIONS: Our findings indicate that TCPs of GBM patients could be increased by escalating radiation doses to intratumoral locations guided by the patient's biology (i.e., cellularity), moreover offering the possibility for personalized RT GBM treatments.
ADVANCES IN KNOWLEDGE: A personalized and voxel level SIB radiotherapy method for GBM is proposed using DW-MRI, which can increase the tumor control probability and maintain organ at risk dose constraints.
引用
- Pang, Kosmin, Li, et al. Isotoxic dose escalated radiotherapy for glioblastoma based on diffusion-weighted MRI and tumor control probability-an in-silico study. Br J Radiol. 2023. PMID: 37102792. doi:10.1259/bjr.20220384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。